Фармакоэкономический анализ применения монтелукаста (Синглона®) в условиях здравоохранения Республики Беларусь

Despite the effectiveness of existing treatments for asthma, alternative therapies have a particular relevance in view of the rapid increase in the prevalence of the disease in the world and the worsening of the financial burden on societies in different countries. Taking into account the importance of asthma in the structure of morbidity, economic burden of this disease in the health care system, and the lack of national prospective studies of appropriate quality, we have carried out the economic evaluation of this condition in children based on the model of decision analysis. In accordance with the findings in 2–6-year-old children with mild asthma a priority therapeutic approach is the use of oral montelukast. In children older than 6 years who are able to learn the technique of inhalation, the priority drug is inhaled glucocorticosteroid.